Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Clinical Microbiology and Infection

Volumn 2, Issue 2, 1996, Pages 91-98

  Ciofu, Oana ^a,b   Jensen, Tim ^a   Pressler, Tacjanci ^a   Johansen, Helle Krogh ^a   Koch, Christian ^a   Høiby, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Burkholderia cepacia; Cystic fibrosis; Meropenem; Pseudomonas aeruginosa

Indexed keywords

EID: 0002597696     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1996.tb00212.x     Document Type: Article

References (22)

1. Pedersen SS, Jensen T, Hoiby N, Koch C, Flensborg EW. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. APMIS 1987; 76: 955-61.
2. Ciofu O, Giwercman B, Pedersen SS, and Hoiby N. Development of resistance as a side-effect of two decades of intensive antipseudomonal treatment in the Danish CF Centre. APMIS 1994; 102: 674-80.
3. Moss RB, Dabin S, Hsu Y-P, Blessing-Moore J, Lewiton NJ. Allergy to semisynthetic penicillins in cystic fibrosis. J Pediatr 1984; 104: 460-6.
4. Koch C, Hjelt K, Pedersen SS, et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other β-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991; 13: S608-11.
5. Pleasants R, Walker TR Samuelson W. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106: 1124-8.
6. Friis B. Chemotherapy of chronic infections with mucoid P. aeruginosa in lower airways in cystic fibrosis. Scand J Infect Dis 1979; 11: 211-17.
7. Anonymous. Pseudomonas ceparia - more than a harmless commensal? Lancet 1992; 339: 1385-6.
8. Livermore DM, Yang Y. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well characterized resistance mechanisms. J Antimicrob Chemother 1989; 24(Suppl A): 149-59.
9. Neu HC, Novelli A, Chin N. In vitro activity and β-lactamase stability of a new carbapenem, SM-7338. J Antimicrob Chemother 1989; 33: 1009-18.
10. Webb AK. The treatment of pulmonary infection in cystic fibrosis. Scand J Infect Dis 1995; Suppl. 96: 24-7.
11. Jensen T, Pedersen SS, Hoiby N, Koch C. Safety of Aztreonam in patients with cystic fibrosis and allergy to β-lactam antibiotics. Rev Infect Dis 1991; 13(suppl 7): S594-7.
12. Ericsson H, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. APMIS 1971; suppl 217: 1-90.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S3. Villanova, PA: NCCLS, 1991.
14. Regelmann WE, Elliott GR, Warwick WJ and Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-21.
15. Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis-Moller A, Koch C. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime and tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scand J Infect Dis 1986; 18: 133-7.
16. Pedersen SS, Presssler T, Jensen T, et al. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Antimicrob Chemother 1987; 19: 101-7.
17. Pedersen SS, Koch C, Hoiby N, Rosendahl K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986; 17: 505-16.
18. Moller NE, Riewerts Eriksen K, Feddersen C, Flensborg EW, Hoiby N. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. Eur J Respir Dis 1982; 63: 130-9.
19. Kropec A, Lemmen S, Wursthorn M, Daschner FD. Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci. Infection 1994; 22(4): 306-8.
20. Sanders CC, Sanders WEJ, Thomson KS, Iaconis JP. Meropenem: activity against resistant Gram-negative bacteria and interactions with β-lactamases. J Antimicrob Chemother 1989; 24(suppl A): 187-96.
21. Govan JRW, Nelson JW. Microbiology of cystic fibrosis lung infections: themes and issues. J R Soc Med 1993; 86(suppl 20): 11-18.
22. Simpson IN, Hunter R, Govan JRW, Nelson JW. Do all Pseudomonas cepacia produce carbapenemases? J Antimicrob Chemother 1993; 32: 339-47.